HypertensionNCT07666607
Pathological Mechanism Study of Aerobic Exercise Regulating Cold Stress-induced Hypertension Via the Thermosensitive Target-mediated Sympathetic Nerve Pathway
An observational study of Hypertension, run by Wang Jingfeng at 1 site in China.
Trial summary
This study focuses on the specificity of thermosensitive targets in populations with hypertension in cold regions, identifies core targets through transcriptome sequencing and clinical validation, and clarifies the regulatory mechanism of moderate-intensity aerobic exercise through a prospective cohort study… Read more about this study
- Who is it for?
- Ages 60 to 69 years
- Conditions the study is for
- Hypertension
- What is being tested?
- Exercise exposure
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 200 participants
- Where
- 1 siteChina
- Study dates
- 4 Oct 2024to 28 Dec 2025
- How long will I take part?
- 16 Weeks
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 69 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Hypertensive population
Who may be able to join
- Same as the inclusion criteria for cold region hypertensive patients in the first stage; No regular moderate-intensity aerobic exercise in the past 3 months (≥3 times per week, ≥30 minutes per session); Exercise risk assessment is low to moderate risk (negative PAR-Q+ questionnaire); Voluntarily participate in this study and sign informed consent.
Who cannot join
- Same as the exclusion criteria in the first stage; Complicated with exercise contraindications (such as severe coronary heart disease, uncontrolled arrhythmia, severe osteoarthropathy, etc.); Unable to complete 16-week follow-up.
Trial locations and contacts
1 site in 1 country.
About this study
This study focuses on the specificity of thermosensitive targets in populations with hypertension in cold regions, identifies core targets through transcriptome sequencing and clinical validation, and clarifies the regulatory mechanism of moderate-intensity aerobic exercise through a prospective cohort study, providing scientific basis for precise prevention and treatment of hypertension in cold regions and personalized exercise intervention.
- Conditions
- Hypertension
- Being tested
- Exercise exposure
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Exercise exposureBehavioural
Patients with essential hypertension in cold regions who met the inclusion criteria were prospectively recruited and divided into an exercise exposure group and a non-exercise control group based on their willingness to accept and adhere to the exercise protocol developed for this study, with a follow-up period of 16 weeks. At baseline and the end of follow-up, we measured the expression of core thermosensitive targets, blood pressure (BP), heart rate variability (HRV), as well as the levels of sympathetic neurotransmitters and indicators of the renin-angiotensin-aldosterone system (RAAS), and compared the changes in these indicators between the two groups.
What is being measured
The primary outcome is the main question the study is designed to answer.
blood pressure (BP)
Systolic blood pressure, unit: mmHg Diastolic blood pressure, unit: mmHg Mean arterial pressure, unit: mmHg
Measured: December 28, 2025
heart rate variability (HRV)
Low Frequency，Unit: nu High Frequency ，Unit: nu Low Frequency / High Frequency ratio Root Mean Square of Successive Differences，Unit: ms Percentage of successive NN intervals differing by more than 50 ms，Unit: % Standard Deviation of all Normal-to-Normal RR intervals，Unit: ms
Measured: 28 December 2025
markers of the sympathetic nervous system (SNS)
Epinephrine, unit: ng/L Norepinephrine, unit: ng/L
Measured: December 28, 2025
mRNA expression of genes
Unit: relative expression level
Measured: December 28, 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jun 2026
- Study start4 Oct 2024
- Primary completion28 Dec 2025
- Study completion28 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (actual)
- Target duration
- 16 Weeks
Sponsor and investigators
- Lead sponsor
- Wang Jingfeng
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Wang Jingfeng, Harbin Sport University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07666607
- Sponsor's protocol ID
- Wjingfeng1103
- Status last verified
- Jun 2026
- First submitted
- 13 Jun 2026
- Last updated
- 24 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pathological Mechanism Study of Aerobic Exercise Regulating Cold Stress-induced Hypertension Via the Thermosensitive Target-mediated Sympathetic Nerve Pathway
- ClinicalTrials.gov ID
- NCT07666607
- Acronym / sponsor ID
- Wjingfeng1103
- Conditions
- Hypertension
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 200 participants (actual)
- Lead sponsor
- Wang JingfengUniversity, hospital or other
- Study start
- 4 Oct 2024 (actual)
- Primary completion
- 28 Dec 2025 (actual)
- Study completion
- 28 Dec 2025 (actual)
- First posted
- 24 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study focuses on the specificity of thermosensitive targets in populations with hypertension in cold regions, identifies core targets through transcriptome sequencing and clinical validation, and clarifies the regulatory mechanism of moderate-intensity aerobic exercise through a prospective cohort study, providing scientific basis for precise prevention and treatment of hypertension in cold regions and personalized exercise intervention.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 16 Weeks
Who may qualify
- Ages
- 60 to 69 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Hypertensive population
Key inclusion criteria (1 listed)
- Same as the inclusion criteria for cold region hypertensive patients in the first stage; No regular moderate-intensity aerobic exercise in the past 3 months (≥3 times per week, ≥30 minutes per session); Exercise risk assessment is low to moderate risk (negative PAR-Q+ questionnaire); Voluntarily participate in this study and sign informed consent.
Key exclusion criteria (1 listed)
- Same as the exclusion criteria in the first stage; Complicated with exercise contraindications (such as severe coronary heart disease, uncontrolled arrhythmia, severe osteoarthropathy, etc.); Unable to complete 16-week follow-up.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Exercise exposurePatients with essential hypertension in cold regions who met the inclusion criteria were prospectively recruited and divided into an exercise exposure group and a non-exercise control group based on their willingness to accept and adhere to the exercise protocol developed for this study, with a follow-up period of 16 weeks. At baseline and the end of follow-up, we measured the expression of core thermosensitive targets, blood pressure (BP), heart rate variability (HRV), as well as the levels of sympathetic neurotransmitters and indicators of the renin-angiotensin-aldosterone system (RAAS), and compared the changes in these indicators between the two groups. | Behavioural | – |
Primary outcome
blood pressure (BP)
Time frame: December 28, 2025
Systolic blood pressure, unit: mmHg Diastolic blood pressure, unit: mmHg Mean arterial pressure, unit: mmHg
heart rate variability (HRV)
Time frame: 28 December 2025
Low Frequency，Unit: nu High Frequency ，Unit: nu Low Frequency / High Frequency ratio Root Mean Square of Successive Differences，Unit: ms Percentage of successive NN intervals differing by more than 50 ms，Unit: % Standard Deviation of all Normal-to-Normal RR intervals，Unit: ms
markers of the sympathetic nervous system (SNS)
Time frame: December 28, 2025
Epinephrine, unit: ng/L Norepinephrine, unit: ng/L
mRNA expression of genes
Time frame: December 28, 2025
Unit: relative expression level
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hypertension, run by Wang Jingfeng at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
blood pressure (BP) (time frame: December 28, 2025). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2026.